Guangzhou Innogen Pharmaceutical Group Co., Ltd (HKG:2591)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
20.90
+0.60 (2.96%)
At close: Mar 27, 2026

HKG:2591 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023
Period Ending
Dec '25 Dec '24 Dec '23
131.51--
Cost of Revenue
14.45--
Gross Profit
117.06--
Selling, General & Admin
254.0586.85255.74
Research & Development
205.78102.51492.11
Other Operating Expenses
4.050.060.06
Operating Expenses
463.88189.42747.91
Operating Income
-346.82-189.42-747.91
Interest Expense
-1.72-0.87-2.32
Interest & Investment Income
13.514.813.97
Currency Exchange Gain (Loss)
-6.50.70.71
Other Non Operating Income (Expenses)
0.180.211.05
EBT Excluding Unusual Items
-341.36-174.58-734.5
Gain (Loss) on Sale of Investments
-0.191.13
Gain (Loss) on Sale of Assets
--4.45-
Other Unusual Items
-4.15-
Pretax Income
-341.36-174.69-733.38
Net Income
-341.36-174.69-733.38
Net Income to Common
-341.36-174.69-733.38
Shares Outstanding (Basic)
434420383
Shares Outstanding (Diluted)
434420383
Shares Change (YoY)
3.44%9.63%-
EPS (Basic)
-0.79-0.42-1.92
EPS (Diluted)
-0.79-0.42-1.92
Free Cash Flow
--166.57-176.64
Free Cash Flow Per Share
--0.40-0.46
Gross Margin
89.01%--
Operating Margin
-263.72%--
Profit Margin
-259.57%--
EBITDA
-332.31-174.91-733.76
EBITDA Margin
-252.69%--
D&A For EBITDA
14.5114.5114.14
EBIT
-346.82-189.42-747.91
EBIT Margin
-263.72%--
Source: S&P Global Market Intelligence. Standard template. Financial Sources.